Science for Organizations: Analysis. Insight. Understanding. Science For Organizations . 75 DeSilva Island Drive . Mill Valley, CA 94941 . Phone 415-381-1041 . Fax 415-381-1046 . Email: info@scifororg.com
HOME ABOUT CASE STUDIES CLIENTS TESTIMONIALS BIBLIOGRAPHY CONTACT
[1] 2 3 4 5 6 7 8 9 10 11 12 13 14 Next>>

347. Gardner, J.D. Increased gastric acid secretion as a possible cause of GERD. Nature Reviews Gastroenterology & Hepatology 7:125-126, 2010.
346. Blondeau, K., Sifrim, D., Gardner, J.D. Continuous distal oesophageal acidification decreases postprandial gastric acidity in healthy human subjects. Aliment Pharmacol Ther 29:561-570, 2009.
345. Gerson L., Triadafilopoulos G., Sahbaie P., Young W., Sloan S., Robinson M., Miner P.B. Jr. and Gardner J.D. Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors. BMC Gastroenterology 8:15-26, 2008
344. Gardner J.D. How do I interpret a positive diagnostic test? Gastrointestinal Endoscopy 66: 891-893, 2007.
343. Gardner J.D., Young W., Sloan S., Robinson M., Miner P.B. Jr. The effects of changing temperature correction factors on measures of acidity calculated from gastric and oesophageal pH recordings. Aliment Pharmacol Ther 23:629-638, 2006.
342. Gardner J.D., Young W., Sloan S., Robinson M., Miner P.B. Jr. The fractal nature of human gastro-oesophageal disease. Aliment Pharmacol Ther 22:823-830, 2005.
341. Gardner J.D., Sloan S., Robinson M., Miner P.B. Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor. Aliment Pharmacol Ther 20:1381-1386, 2004.
340. Gardner J.D., Sloan S., Robinson M., Miner P.B. Oesophageal pH has a power-law distribution in control and gastro-oesophageal reflux disease subjects. Aliment Pharmacol Ther 20:1373-1379, 2004.
339. Gardner J.D., Gallo-Torres H., Sloan S., Robinson M., Miner P.B. Jr. The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis. Aliment Pharmacol Ther 18:891-905, 2003.
338. Gardner J.D., Sloan S., Robinson M., Miner P.B. Jr. Heartburn severity can predict pathologic oesophageal reflux in gastro-oesophageal reflux patients treated with a proton pump inhibitor. Aliment Pharmacol Ther 18:133-140, 2003.
337. Gardner, J.D., Sloan, S., Miner, P.B. Jr., Robinson, M. Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastroesophageal reflux disease treated with a proton pump inhibitor. Aliment Pharmacol Ther 17:954-964, 2003.
336. Gardner, J.D., Sloan, S., Miner, P.B. Jr., Robinson, M. Meal-stimulated gastric acid secretion and integrated gastric acidity in gastroesophageal reflux disease. Aliment Pharmacol Ther 17:945-953, 2003.
335. Gardner, J.D., Rodriguez-Stanley, S., Robinson, M., Miner, P.B. Jr. Cisapride inhibits meal-stimulated gastric acid secretion and postprandial gastric acidity in subjects with gastroesophageal reflux disease. Aliment Pharmacol Ther 16:1819-1829, 2002.
334. Gardner, J.D., Ciociola, A.A., Robinson, M, McIsaac, R.L. Determination of the time of onset of action of ranitidine and famotidine on gastric acidity. Aliment Pharmacol Ther 16:1-11, 2002.
333. Gardner, J.D., Ciociola, A.A., Robinson, M. Measurement of meal-stimulated gastric acid secretion by in vivo gastric autotitration. J. Appl. Physiol. 92: 427-434, 2002
332. Robinson, M., Rodriguez-Stanley, S., Ciociola, A.A., Filinto, J., Zubaidi, S, Miner, P.B. Jr., Gardner, J.D. Control of nocturnal gastric acidity: a role for low dose bedtime ranitidine to supplement daily omeprazole. Dig. Dis. Sci. 47: 265-273, 2002.
331. Gardner, J.D., Perdomo, C., Sloan, S., Hahne, W.F., Barth, J.A., Rodriguez-Stanley, S., and Robinson, M. Integrated acidity and rabeprazole pharmacology. Aliment. Pharmacol. Ther. 16: 455-464,2002.
330. Gardner, J.D., Rodriguez-Stanley, S., and Robinson, M. Integrated acidity and the pathophysiology of GERD. Am. J. Gastroenterol. 96: 1363-1370, 2001.
329. Robinson, M., Rodriguez-Stanley, S., Ciociola, A.A., Filinto, J., Zubaidi, S, Miner, P..B. Jr., Gardner, J.D. Synergy between low dose ranitidine and antacid in reducing gastric and esophageal acidity and relieving meal-induced heartburn. Aliment. Pharmacol. Ther. 15: 1365-1374, 2001.
328. Joshi, S. N. and Gardner, J.D. Gastrin and colon cancer: A unifying hypothesis. Dig, Dis. 14: 334-344, 1996.
327. Bastani, B., Yang, L., Baldassare, J.J., Pollo, D.A. and Gardner, J.D. Cellular distributions of isoforms of protein kinase C (PKC) in pancreatic acini. Biochim. Biophys. Acta. 1269: 307-315, 1995.
326. Huang, S-C., Talkad, V.D., Fortune, K.P., Jonnalagadda, S., Severi, C., Delle Fave, G. and Gardner, J.D. Modulation of cholecystokinin activity by albumin. Proc. Natl. Acad. Sci. USA. 92: 10312-10316, 1995.
325. Huang, S-C., Fortune, K.P., Wank, S.A., Kopin, A.S. and Gardner, J.D. Multiple affinity states of different cholecystokinin (CCK) receptors. J. Biol. Chem. 269: 26121-26126, 1994
324. Pollo, D.A., Baldassare, J.J., Honda, T., Henderson, P.A., Talkad, V.D. and Gardner, J.D. Effects of cholecystokinin (CCK) and other secretagogues on isoforms of protein kinase C (PKC) in pancreatic acini. Biochim. Biophys. Acta. 1224: 127-138, 1994.
323. Pandya, P.K., Huang, S-C., Talkad, V.D., Wank, S.A. and Gardner, J.D. Biochemical regulation of the three different states of the cholecystokinin (CCK) receptor in pancreatic acini. Biochim. Biophys. Acta. 1224: 117-126, 1994

[1] 2 3 4 5 6 7 8 9 10 11 12 13 14 Next>>


Search Bibliography by Keyword:
Home . About Us . Case Studies . Clients . Testimonials . Bibliography . Contact Us
© 2006 Science for Organizations . All Rights Reserved